CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Gossamer Bio announces $250m in funding to advance seralutinib

seralutinibPositive
AI Analysis

Summary

Gossamer Bio announced a private placement agreement of up to $250m, with $150m in committed capital to support seralutinib development and potential FDA approval.

Importance:5/10
Sentiment:
0.60
fundingprivate placementseralutinibFDA approvalcapital raise

Read the original article

Published by Pharmaceutical Technology on August 24, 2026 9:15 AM

Read Original